» Authors » David J Delgado

David J Delgado

Explore the profile of David J Delgado including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 204
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
McCurdy R, Delgado D, Baxter J, Berghella V
J Matern Fetal Neonatal Med . 2020 Aug; 35(14):2781-2787. PMID: 32762274
Background: Currently, all obese women in the United States (US) are recommend to gain the same amount of weight during pregnancy, regardless of class of obesity. Limited literature has looked...
2.
Cunningham A, Delgado D, Jackson J, Crawford A, Jabbour S, Lieberthal R, et al.
J Am Board Fam Med . 2018 Mar; 31(2):279-281. PMID: 29535245
Purpose: Group medical visits (GMVs), which combine 1-on-1 clinical consultations and group self-management education, have emerged as a promising vehicle for supporting type 2 diabetes management in primary care. However,...
3.
Loftus Jr E, Friedman H, Delgado D, Sandborn W
Inflamm Bowel Dis . 2009 Jan; 15(4):566-75. PMID: 19143006
Background: We describe colectomy subtypes, follow-up surgical and diagnostic procedures, complications, and direct medical charges occurring within 180 days of colectomy among privately insured patients with ulcerative colitis (UC). Methods:...
4.
Loftus Jr E, Delgado D, Friedman H, Sandborn W
Am J Gastroenterol . 2008 Jun; 103(7):1737-45. PMID: 18564126
Purpose: We sought to describe the types of colectomy, follow-up surgical/diagnostic procedures, and complications occurring within 180 days of colectomy in a population of privately insured individuals with ulcerative colitis...
5.
Rabinowitz A, Weiner N, Tronic B, Fridman M, F Liberman R, Delgado D
Leuk Lymphoma . 2006 Jun; 47(5):853-8. PMID: 16753869
Chemotherapy used to treat lymphoma can cause severe neutropenia. Risk models have identified factors that predict neutropenia across all chemotherapy cycles. We used clinical information obtained during pretreatment evaluation to...
6.
Chrischilles E, Klepser D, Brooks J, Voelker M, Chen-Hardee S, Scott S, et al.
Pharmacotherapy . 2005 May; 25(5):668-75. PMID: 15899728
Study Objective: To estimate the costs of hospitalization for neutropenia among chemotherapy-treated patients with newly diagnosed non-Hodgkin's lymphoma and to assess baseline patient factors associated with these costs. Design: Retrospective...
7.
Lyman G, Morrison V, Dale D, Crawford J, Delgado D, Fridman M
Leuk Lymphoma . 2004 Feb; 44(12):2069-76. PMID: 14959849
We sought to identify risk factors associated with the time to febrile neutropenia in patients with intermediate-grade, non-Hodgkin's lymphoma (NHL) who were receiving treatment with CHOP chemotherapy. Data were collected...
8.
Lyman G, Delgado D
Cancer . 2003 Nov; 98(11):2402-9. PMID: 14635075
Background: Hospitalization for chemotherapy-induced febrile neutropenia is associated with substantial cost and may negatively impact clinical outcome due to associated dose attenuation. Methods: Medical records of 1355 patients with intermediate-grade...
9.
Scott S, Chrischilles E, Link B, Delgado D, Fridman M, Stolshek B
J Manag Care Pharm . 2003 Nov; 9(2 Suppl):15-21. PMID: 14613340
Background: Filgrastim prophylaxis lessens the occurrence of febrile neutropenia in patients with non-Hodgkin.s lymphoma (NHL) treated with chemotherapy, but differences in days of therapy and mode (primary or secondary) of...
10.
Chrischilles E, Link B, Scott S, Delgado D, Fridman M
Cancer Control . 2003 Oct; 10(5):396-403. PMID: 14581895
Background: Six to eight cycles of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard for intermediate-grade non-Hodgkin's lymphoma (NHL) but is associated with toxicity that may cause premature termination...